UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

Call Start: 16:30 January 1, 0000 5:27 PM ET Axonics, Inc. (NASDAQ:AXNX) Q2 2023 Earnings Conference Call July 27, 2023 16:30 ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Polark - Wolfe Research Shagun Singh - RBC Capital Markets Richard Newitter - Truist Securities Adam Maeder - Piper Sandler Mike Matson - Needham & ...

Axonics, Inc. (NASDAQ:AXNX) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Chris Pasquale - Nephron Research Richard Newitter - Truist Securities Nathan Treyback - Wells Fargo Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Shagun Singh - RBC Capital Markets Mike Matson - Needham and Company Anthony Petrone - Mizuho Securities Michael Sarcone - Jefferies Operato ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

Axonics, Inc. (NASDAQ:AXNX) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Chris Pasquale - Nephron Research Cecilia Furlong - Morgan Stanley David Rescott - Truist Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Shagun Singh - RBC Capital Markets Michael Sarcone - Jefferies Mike Matson - Needham and ...

| --- | --- | |----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------| | | Commission File Number: 001-38721 _________________________________________________________________ | | (Exact name of | Axonics, Inc. registrant as specified in its charter) _________________________________________________________________ | | Delaware | 45-4744083 | | incorporat ...

Financial Performance - Net revenue for the three months ended September 30, 2022, was $70.384 million, a 50.0% increase from $46.913 million in the same period of 2021[13] - Gross profit for the three months ended September 30, 2022, was $51.260 million, compared to $31.194 million in the prior year, reflecting a gross margin improvement[13] - The net loss for the three months ended September 30, 2022, was $16.252 million, slightly improved from a net loss of $17.250 million in the same quarter of 2021[13] - The company reported a comprehensive loss of $28.309 million for the three months ended September 30, 2022, compared to a comprehensive loss of $22.388 million in the same period of 2021[13] - The company reported a net loss of $60.363 million for the nine months ended September 30, 2022, compared to a net loss of $64.901 million for the same period in 2021[21] - Total net revenue for the nine months ended September 30, 2022, was $187.8 million, a 47.7% increase from $127.2 million in the same period of 2021[35] Assets and Liabilities - Total current assets increased to $449.361 million as of September 30, 2022, up from $321.317 million at December 31, 2021, representing a 40.0% growth[9] - Total liabilities rose to $82.760 million as of September 30, 2022, compared to $65.507 million at December 31, 2021, indicating a 26.3% increase[10] - Cash and cash equivalents increased to $241.331 million as of September 30, 2022, from $220.878 million at December 31, 2021, reflecting a 9.0% increase[9] - The total stockholders' equity as of September 30, 2022, was $549.518 million, up from $482.438 million at December 31, 2021, representing a 13.9% increase[10] - The company had cash, cash equivalents, and short-term investments of $350.0 million as of September 30, 2022, with no material exposure to interest rate changes[152] Expenses - Research and development expenses for the three months ended September 30, 2022, were $7.936 million, down from $8.648 million in the prior year, showing an 8.2% decrease[13] - The company experienced a depreciation and amortization expense of $8.841 million for the nine months ended September 30, 2022, compared to $6.483 million for the same period in 2021[21] - The company’s stock-based compensation expense increased to $23.261 million for the nine months ended September 30, 2022, from $18.320 million in the same period of 2021[21] - Advertising expenses totaled $6.0 million and $15.5 million for the three and nine months ended September 30, 2022, respectively, compared to $2.6 million and $5.5 million for the same periods in 2021, representing an increase of 130.8% and 181.8%[63] Inventory and Assets - As of September 30, 2022, the company reported $34.1 million in finished goods inventory, $5.7 million in work-in-process inventory, and $18.0 million in raw materials inventory, net of reserves[51] - The carrying amount of goodwill decreased from $105.5 million as of December 31, 2021, to $86.9 million as of September 30, 2022, primarily due to foreign currency translation adjustments[98] - Total intangible assets as of September 30, 2022, were valued at $81.8 million, down from $106.5 million as of December 31, 2021[100] Financing and Capital - The company generated $128.498 million in proceeds from a follow-on public offering completed on August 5, 2022, at an offering price of $63.85 per share[26] - The Company incurred net losses of $60.4 million for the nine months ended September 30, 2022, compared to $64.9 million for the same period in 2021, with an accumulated deficit of $374.9 million as of September 30, 2022[29] - The Company may need to raise additional financing in the future, which could lead to dilution for existing stockholders or unfavorable terms[29] Operational Insights - The ongoing COVID-19 pandemic has adversely affected the Company's business, particularly through the cancellation or delay of elective procedures, which could materially harm revenues[31] - The Company continues to invest significantly in sales and marketing activities to support the commercialization of its products both in the United States and internationally[29] - The company is currently engaged in the Medtronic Litigation, which could materially affect its business and financial position, with a jury trial scheduled for April 2023[80] Future Outlook - The company provided guidance for the next quarter, expecting revenue to be between $A million and $B million, indicating a growth rate of C%[168] - New product launches are anticipated to drive future growth, with the introduction of Product X expected to generate an additional $D million in revenue[166] - Market expansion efforts are underway, with plans to enter the European market by Q1 of next year, targeting an additional $F million in revenue[168] - The management team expressed confidence in achieving long-term growth targets, emphasizing a commitment to innovation and market leadership[166]

Axonics, Inc. (NASDAQ:AXNX) Q3 2022 Earnings Conference Call October 31, 2022 4:30 PM ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Chris Pasquale - Nephron Research Travis Steed - Bank of America Securities David Rescott - Truist Cecilia Furlong - Morgan Stanley Michael Polark - Wolfe Research Mike Matson - Needham & Company Operat ...

Axonics, Inc. (NASDAQ:AXNX) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Adam Maeder - Piper Sandler Cecilia Furlong - Morgan Stanley Lawrence Biegelsen - Wells Fargo Securities Mike Polark - Wolfe Research Mike Matson - Needham & Company Operator Good day and thank you for standi ...